Telix Pharmaceuticals (TLX) Long-Term Investments (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Long-Term Investments for 3 consecutive years, with $37.1 million the latest figure, recorded in Q4 2025.

• Quarterly Long-Term Investments fell 6.36% year-over-year to $37.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $37.1 million (down 6.36% YoY) and the FY2025 annual result came in at $37.1 million, up 6.76% from the prior year.
• Long-Term Investments slipped to $37.1 million in Q4 2025 per TLX's latest filing, from $39.6 million in the prior quarter.
• Over the last five years, Long-Term Investments for TLX reached as high as $39.6 million in Q4 2024 and fell as low as $8.7 million in Q4 2023.
• A 3-year average of $28.5 million and a median of $37.1 million in 2025 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2024 — Long-Term Investments jumped 357.53% — and 2025, when it dropped 6.36%.
• Year by year, Long-Term Investments stood at $8.7 million in 2023, then surged by 357.53% to $39.6 million in 2024, then fell by 6.36% to $37.1 million in 2025.
• According to Business Quant data, Long-Term Investments over the past three periods registered $37.1 million, $39.6 million, and $8.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.